Presentation will include an update on the development and launch preparations of Cylembio™ (imsapepimut and etimupepimut, adjuvanted) NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: ...

Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in ...

In the initial publication in 2021, the KETYNOTE-564 trial demonstrated that adjuvant pembrolizumab was associated with ...

Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab ...

DALLAS, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView ® System, which received Breakthrough Device Designation from ...

The 3-year invasive disease-free survival rate was 84.6% in the atezolizumab-chemotherapy arm and 86.4% in the chemotherapy-alone arm. Adding atezolizumab to adjuvant chemotherapy does not improve ...

Nivolumab plus chemotherapy had the highest surgical resection rate (OR = 1.71, 95% CI: 0.87–3.40), while pembrolizumab plus chemotherapy had the best R0 surgical resection rate (OR = 2.20, 95% CI: ...

2 The ongoing multicenter international randomized phase 2 study INTerpath-004 (NCT06307431) is comparing a PCV in combination with pembrolizumab (Keytruda) vs placebo plus pembrolizumab in the ...

Pembrolizumab is recommended, within its marketing authorisation, as an option for the adjuvant treatment of non-small-cell lung cancer (NSCLC) with a high risk of recurrence after complete resection ...

The study was not designed to statistically assess outcomes in subgroups, but it's notable that in the post-adjuvant subgroup, PFS and OS with lenvatinib plus pembrolizumab were prolonged versus ...

2 This randomized, phase III trial enrolled 702 patients with high-risk MIUC (e.g., patients with pN+, pT3/T4 disease, or persistent MIUC despite neoadjuvant therapy), randomized to receive either ...